Corporate | 4 September 2008 08:00
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
International Brachytherapy s.a. (IBt-BEBIG), a European manufacturer of
implants for the treatment of prostate cancer, and consolidated within
Eckert & Ziegler, announces that it has won a large tender to supply
IsoCord® to the renowned Madrid cancer research center Hospital
Universitario Ramón y Cajal.
This contract, for product valued in excess of 0.7 million Euros, will
further strengthen the position of the company on the Spanish market as a
supplier of radiotherapy products. The contract is the fifth long-term
supply contract for implants signed with a Spanish hospital since IBt-BEBIG
incorporated its Spanish subsidiary earlier this year.
IsoCord® consists of a selectable number of linked seeds used primarily in
the treatment of prostate cancer. The IsoCord® system with its convenient
and well shielded strand cassette and dispensing device make for quicker
procedures and reduced radiation exposure to personnel in the operating
room. Long terms study have shown that permanent brachytherapy seed
implants provide disease control at least as good as classical radical
prostatectomy and external beam radiotherapy but with fewer side effects
for patients. Prostate cancer is the commonest form of cancer in men, with
about 135,000 new cases diagnosed in Europe every year.
IBt-BEBIG designs, produces and markets worldwide a complete range of
radiotherapy implants used in permanent brachytherapy. The group today
includes subsidiaries based in Germany, France, UK, Ireland, Spain, and
Italy as well as a large number of distributors spread throughout the
world.
Contacts
François Blondel, CEO
Laurence Goemaere, Investors Relations Manager
Tel: +32 (0)064.520811
E-mail: ir@ibt.be
Website: www.ibt.be
04.09.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: thomas.scheuch@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------